unapproved forms of colchicine is banned by FDA

Companies that manufacture, distribute, and/or market unapproved formulations of the oral, single ingredient forms of the gout drug colchicine have been ordered to

FDA approves new intravenous gout treatment

On September 14, 2010, Savient Pharmaceuticals and the US Food and Drug Administration (FDA) announced the approval of Krystexxa (pegloticase), an intravenous (IV) treatment for chronic gout in adults whose conditions have been refractory to conventional therapy. Krystexxa is a pegylated uric-acid–specific enzyme that

TNF antagonists in rheumatic patients linked with increased hospitalization for varicella zoster

Rheumatic disease patients who are exposed to tumor necrosis factor antagonists have a 10-fold increased risk of hospitalization for varicella zoster virus infections, compared with the general population, according to a secondary analysis of two large databases.
Nonetheless, the absolute incidence of varicella-related hospitalizations remains